# A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

> **NCT01641939** · PHASE2,PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 415 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Taxane
- **DRUG:** trastuzumab emtansine
- **DRUG:** trastuzumab emtansine

## Key facts

- **NCT ID:** NCT01641939
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09-03
- **Primary completion:** 2015-06-30
- **Final completion:** 2016-04-30
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641939, "A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT01641939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*